Trogenix Publishes Glioblastoma Gene Therapy Research in Nature

Trogenix Ltd., a Brain Tumor Investment Fund™ (BTIF) portfolio company, has published new preclinical research on its synthetic super-enhancer gene therapy platform for glioblastoma in the journal Nature. The paper describes the technology behind Trogenix’s lead program, which the company plans to advance into a first-in-human clinical trial later this year.

The full paper is available in Nature here, and Trogenix’s announcement of the publication can be read here.

BTIF is not responsible for the content of third-party press releases.